For most people who die of cancer, the spread of the initial tumor is to blame. "Metastasis is what kills most cancer patients," says Serge Fuchs, a professor in Penn's School of Veterinary Medicine. "Yet there are not many, ...
May 28, 2020
0
191
A study at The University of Texas MD Anderson Cancer Center showed that circulating tumor cells (CTCs), a form of liquid biopsy, was independently associated with melanoma relapse, suggesting CTC assessment may be useful ...
Feb 3, 2020
0
4
A patient-specific tumor organoid platform developed by Wake Forest Institute for Regenerative Medicine (WFIRM) researchers and their cancer center colleagues could someday take the guessing game out of immunotherapy treatments. ...
Jan 21, 2020
0
9
Researchers at Children's Medical Center Research Institute at UT Southwestern (CRI) have uncovered why certain melanoma cells are more likely to spread through the body. The discovery opens up a potential new avenue of treatment ...
Dec 19, 2019
0
205
Immunotherapy has become a standard treatment approach for several types of cancer, including melanoma. However, tumors can escape immune cell detection even with the use of immunotherapies. In a new study published in Cancer ...
Nov 1, 2019
0
239
Patients with advanced melanoma have been able to live longer because of several newly approved targeted treatment options, including BRAF and MEK inhibitors. However, patients will often have different responses to the same ...
Oct 8, 2019
0
17
Melanoma is the least common but one of the most deadly skin cancers. It accounts for only about one percent of all cases globally, but the majority of skin cancer deaths. Accurate, timely and reliable diagnosis of cutaneous ...
Sep 30, 2019
0
20
Using a small noncoding RNA, microRNA 211, and tools that track the stability and decay of the protein-coding and noncoding RNAs in lab-grown melanoma cells, a team led by a Johns Hopkins Kimmel Cancer Center researcher identified ...
Sep 25, 2019
0
7
Brain metastases are among the deadliest tumor metastases, with a median survival period of less than one year, and the incidence of brain metastasis is rising.
Aug 19, 2019
0
2261
A study from Vanderbilt-Ingram Cancer Center and the Department of Veterans Affairs led by Anna Vilgelm, MD, Ph.D., and Ann Richmond, Ph.D., has identified a possible second-line treatment for melanoma patients.
Aug 15, 2019
0
32
